Drug Search Results
More Filters [+]

Doconexent

Alternative Names: doconexent, docosahexaenoic acid, efalex, SC-411, SC411
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PPAR Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Bangladesh | Belgium | Canada | Chile | India | Malaysia | Pakistan | Philippines | Taiwan | United Arab Emirates | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Doconexent

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events